Clinical Trial Goal
To find out:
- The highest dose of JNJ-79635322 that's safe to give
- If JNJ-79635322 is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have multiple myeloma that has relapsed or is refractory
- Do not have any of the following:
- Plasma cell leukemia
- POEMS syndrome
- Primary light chain amyloidosis
- Waldenstrom's macroglobulinemia
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not had an autologous (your own cells) BMT in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
JNJ-79635322 is a trispecific antibody that targets CD3, BCMA and GPRC5D in certain cells.
You’ll get:
You’ll get:
- JNJ-79635322 – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to about 2.5 years.
The Food and Drug Administration (FDA) has not yet approved JNJ-79635322.
Locations
Sponsors
lead: Janssen Research & Development, LLC
